177 related articles for article (PubMed ID: 32294481)
1. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.
Wysock JS; Becher E; Persily J; Loeb S; Lepor H
Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481
[TBL] [Abstract][Full Text] [Related]
2. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
3. Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
Punnen S; Nahar B; Soodana-Prakash N; Koru-Sengul T; Stoyanova R; Pollack A; Kava B; Gonzalgo ML; Ritch CR; Parekh DJ
PLoS One; 2018; 13(8):e0201384. PubMed ID: 30092002
[TBL] [Abstract][Full Text] [Related]
4. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
5. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
Busetto GM; Del Giudice F; Maggi M; De Marco F; Porreca A; Sperduti I; Magliocca FM; Salciccia S; Chung BI; De Berardinis E; Sciarra A
World J Urol; 2021 Jun; 39(6):1869-1877. PubMed ID: 32681273
[TBL] [Abstract][Full Text] [Related]
6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
7. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
8. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
10. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.
Stanton WN; Crawford ED; Arangua PB; La Rosa FG; van Bokhoven A; Lucia MS; Poage WL; Partin A; Maroni P; Werahera PN
Can J Urol; 2020 Feb; 27(1):10080-10085. PubMed ID: 32065862
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.
Bang S; Yu J; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
Sci Rep; 2021 Nov; 11(1):21951. PubMed ID: 34753938
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
13. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.
Ferro M; Rocco B; Maggi M; Lucarelli G; Falagario UG; Del Giudice F; Crocetto F; Barone B; La Civita E; Lasorsa F; Brescia A; Catellani M; Busetto GM; Tataru OS; Terracciano D
Expert Rev Mol Diagn; 2023; 23(12):1061-1070. PubMed ID: 37897252
[TBL] [Abstract][Full Text] [Related]
14. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
15. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
[TBL] [Abstract][Full Text] [Related]
16. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
17. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
18. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
19. The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
Cosma I; Tennstedt-Schenk C; Winzler S; Psychogios MN; Pfeil A; Teichgraeber U; Malich A; Papageorgiou I
PLoS One; 2019; 14(12):e0227031. PubMed ID: 31869380
[TBL] [Abstract][Full Text] [Related]
20. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.
Maggi M; Del Giudice F; Falagario UG; Cocci A; Russo GI; Di Mauro M; Sepe GS; Galasso F; Leonardi R; Iacona G; Carroll PR; Cooperberg MR; Porreca A; Ferro M; Lucarelli G; Terracciano D; Cormio L; Carrieri G; De Berardinis E; Sciarra A; Busetto GM
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
